Citius Oncology, Inc. CTOR
1.05
0.00
0.00%
as of 25 Sep
- Market cap
- $97.6M
- P/E
- 0.0×
Follow CTOR
| Sep '25 | Sep '24 | Dec '23 | Sep '23 | Dec '22 | Sep '22 | Dec '21 | Sep '21 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
0.56 | 0.34 | 0.03 | 0.37 | 11.86 | 1.33 | 0.93 | — |
Net Debt/EBITDA |
(0.40) | (0.21) | (0.31) | (1.61) | 2.09 | (1.40) | (12.94) | 0.00 |
Debt/Assets |
13.19% | 5.20% | 0.47% | 40.85% | 0.00% | 75.18% | 103.40% | 0.00% |
Debt/Equity |
0.30 | 0.10 | (0.17) | 0.76 | 0.00 | (966.00) | (12.94) | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.22 | (0.01) | (0.25) | 0.00 | (0.13) | 0.00 | 0.00 | 0.00 |
Capex/Depreciation |
0.00 | 0.00 | — | — | — | 0.00 | — | 0.00 |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (54.42%) | (95.80%) | 20.55% | (98.12%) | 220.56% | (7,394.17%) | 0.00% | 0.00% | |
| (26.72%) | (26.94%) | 4.02% | (21.91%) | 1.11% | 198.64% | (15.98%) | 0.00% | |
ROIC |
(27.10%) | (25.45%) | 0.00% | (16.82%) | (153.31%) | (44.72%) | (5.23%) | 0.00% |
Return on Tangible Assets |
112.81% | 97.32% | (121.72%) | 95.38% | 110.22% | 596.87% | 100.00% | 0.00% |
Research and Development Expense of Revenue |
0.00% | 0.00% | — | 0.00% | — | 0.00% | — | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | — | 0.00% | — | — | — | — |
Free Cash Flow per Share |
(0.15) | (0.07) | (0.26) | 0.00 | (0.03) | 0.00 | 0.00 | 0.00 |
Cash per Share |
0.05 | 0.00 | 0.01 | 0.00 | 0.16 | — | 0.00 | — |
Shareholders Equity per Share |
0.61 | 0.68 | (0.85) | 0.38 | 0.19 | 0.00 | 0.00 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
0.61 | 0.68 | (0.85) | 0.38 | 0.19 | 0.00 | 0.00 | — |
Free Cash Flow |
(11.24) | (4.87) | (0.60) | — | (0.05) | 0.00 | — | 0.00 |
Working Capital |
(21.95) | (21.73) | (1.99) | (13.31) | 0.35 | 0.06 | (0.01) | — |
Capital Expenditures |
(5.75) | (5.00) | — | — | — | 0.00 | — | 0.00 |
Net Current Asset Value |
(28.53) | (27.26) | (74.55) | (14.46) | (67.47) | 0.06 | (0.01) | — |
| Other line items | ||||||||
Quick Ratio |
0.08 | 0.00 | 0.02 | 0.00 | 9.09 | 0.00 | 0.00 | — |
Depreciation/Fixed assets |
— | — | — | — | — | 0.00 | — | 0.00 |
Cash ROIC |
(8.84%) | 0.25% | 37.35% | 0.00% | (7.56%) | 0.00% | 0.00% | 0.00% |
Accounts Payable Turnover |
0.00 | 0.00 | — | — | — | — | — | — |
Inventory Turnover |
0.00 | — | — | — | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | — | 0.00 | — | — | — | — |
Days of Inventory on Hand |
0.00 | 0.00 | — | — | — | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — |
Operating CF per Share |
(0.07) | 0.00 | (0.26) | 0.00 | (0.03) | — | 0.00 | 0.00 |
Capex per Share |
(0.08) | (0.07) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Payables |
8.47 | 2.50 | — | — | — | — | — | — |
Average Inventory |
15.28 | — | — | — | — | — | — | — |
Average Assets |
92.66 | 78.50 | 60.18 | 57.96 | 34.22 | 0.19 | 0.06 | — |
Average Common Equity |
45.50 | 22.08 | 11.77 | 12.94 | 0.17 | (0.01) | — | — |
Capex to Sales |
0.00 | 0.00 | — | — | — | 0.00 | — | 0.00 |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates